Hugo Ferreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hugo Ferreira has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- André Ferreira
Division of Nephrology, Department of Medicine, Instituto Português de Oncologia do Porto, FG, E.P.E., Porto, Portugal
3 shared publications - José Maximino Costa
Nephrology Department, Instituto Português de Oncologia do Porto, Porto, Portugal
3 shared publications Ana Paiva
Division of Nephrology, Department of Medicine, Instituto Português de Oncologia do Porto, FG, E.P.E., Porto, Portugal
2 shared publications- Ana Paiva
Flow Cytometry Unit, Clinical Pathology Department, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal
2 shared publications - Inês Coelho
Division of Nephrology, Department of Medicine, Instituto Português de Oncologia do Porto, FG, E.P.E., Porto, Portugal
2 shared publications Marina Reis
Division of Nephrology, Department of Medicine, Instituto Português de Oncologia do Porto, FG, E.P.E., Porto, Portugal
2 shared publications
Latest Publications
- Open Access
- 7 August 2025
- Published by Elsevier in Nefrología (English Edition)
- Vol. 45 (6) , 501332
Pharmacological nephrotoxicity profile in a comprehensive cancer center: What changed in two decades and predictors for the need for haemodialysis and mortality
- 7 August 2025
- Published by Elsevier in Nefrología (English Edition)
- Vol. 45 (6) , 501332
Open AccessPharmacological nephrotoxicity profile in a comprehensive cancer center: What changed in two decades and predictors for the need for haemodialysis and mortality
- Open Access
- 3 June 2025
- Published by Elsevier in Nefrología
- Vol. 45 (6)
Pharmacological nephrotoxicity profile in a comprehensive cancer center: What changed in two decades and predictors for the need for haemodialysis and mortality
- 3 June 2025
- Published by Elsevier in Nefrología
- Vol. 45 (6)
Open AccessPharmacological nephrotoxicity profile in a comprehensive cancer center: What changed in two decades and predictors for the need for haemodialysis and mortality
- 6 May 2025
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (5) , 1525-1527
Hypercalcemia in a patient with small bowel gastrointestinal stromal tumor: a quiz
- 6 May 2025
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (5) , 1525-1527
Hypercalcemia in a patient with small bowel gastrointestinal stromal tumor: a quiz
- Open Access
- 1 November 2022
- Published by Elsevier in Nefrología
- Vol. 42 (6) , 656-663
Acute kidney injury after allogeneic hematopoietic stem cell transplantation – Predictors and survival impact: A single center retrospective study
- 1 November 2022
- Published by Elsevier in Nefrología
- Vol. 42 (6) , 656-663
Open AccessAcute kidney injury after allogeneic hematopoietic stem cell transplantation – Predictors and survival impact: A single center retrospective study
- Open Access
- 1 September 2021
- Published by Wolters Kluwer Health in Porto Biomedical Journal
- Vol. 6 (5) , e142
IgA nephropathy in IgG kappa multiple myeloma
Multiple myeloma (MM) frequently affects kidney function through multiple mechanisms. Nonetheless, some patients develop kidney injury due to other causes. A 54-year-old woman was diagnosed with IgG kappa MM developed IgA nephropathy without cast nephropathy. Further studies did not show criteria for MM progression or other causes. This case highlights the need for further investigation of kidney injury in MM patients (such as toxicity of previous drugs, infectious events, or immune-mediated disorders).
- 1 September 2021
- Published by Wolters Kluwer Health in Porto Biomedical Journal
- Vol. 6 (5) , e142
Open AccessIgA nephropathy in IgG kappa multiple myeloma
Multiple myeloma (MM) frequently affects kidney function through multiple mechanisms. Nonetheless, some patients develop kidney injury due to other causes. A 54-year-old woman was diagnosed with IgG kappa MM developed IgA nephropathy without cast nephropathy. Further studies did not show criteria for MM progression or other causes. This case highlights the need for further investigation of kidney injury in MM patients (such as toxicity of previous drugs, infectious events, or immune-mediated disorders).
- 27 September 2017
- Published by Morressier GmbH
Lercanidipine associated chylous ascitis in a patient submitted to peritoneal dialysis catheter insertion
- 27 September 2017
- Published by Morressier GmbH
Lercanidipine associated chylous ascitis in a patient submitted to peritoneal dialysis catheter insertion